Pirrnenol hydrochloride is a long-lasting Class la antiarrhythmic agent introduced
in Japan in 1994. The spectrum of antiarrhythmic activity of pirmenol includes atrial
and ventricular arrhythmias of diverse etiology. In clinical trials, pirmenol was found
effective in the short- and mid-term treatment of chronic premature ventricular
beats, with or without underlying heart disease. In patients with supraventricular
tachycardia, a single oral dose of pirmenol was highly effective in suppressing
induction of tachycardia with adequate hemodynamic tolerance. Since pirmenol is
highly effective by both intravenous and oral routes, it enables immediate
suppression, prevention, or termination of cardiac arrhythmias and facilitates the
transition to oral prophylactic therapy.
